Immunosuppression News and Research

RSS

Immunosuppression involves an act that reduces the activation or efficacy of the immune system. Some portions of the immune system itself have immuno-suppressive effects on other parts of the immune system, and immunosuppression may occur as an adverse reaction to treatment of other conditions.

Novel immunosuppressant improves kidney function and quality of life after transplantation

The Phase 2 BESTOW clinical trial showed that tegoprubart (a novel anti-CD40L antibody therapy) was better at preserving kidney function than tacrolimus (the current standard of care) in immunosuppressive regimens in adults receiving their first kidney transplant.

23 Oct 2026

New gene-editing platform gives doctors control over cell therapies

An Australian clinician-led research team has developed a gene-editing platform that could give doctors more control over cell therapies, making them more practical for patients with complex immune conditions.

20 Oct 2026

First patient dosed in Phase 1 clinical trial of new cancer drug

On August 18, 2026, in Japan, the Department of New Experimental Therapeutics and Early-Phase 1 Drug Development Service at Kansai Medical University Hospital, led by Professor Toshio SHIMIZU, administered DS1025 to the first patient worldwide as part of a global, multicenter First-in-Human Phase 1 clinical trial sponsored by Daiichi Sankyo.

19 Oct 2026

Polymeric nanomedicine strategies improve solid tumor immunotherapy outcomes

Solid tumors are not merely collections of malignant cells but complex ecosystems comprising tumor cells, stromal cells, and the extracellular matrix (ECM).

9 Oct 2026

Neuromedin U drives immune suppression in aggressive prostate cancer

A new study from The Wistar Institute has found a link between the nervous system and the rapid development of neuroendocrine prostate cancer (NEPC), an aggressive form of the disease.

24 Sep 2026

Multiple immunosuppressive therapies increase infection risks for cancer patients

Retrospective analysis of more than 20,000 patient records identifies opportunities for risk-mitigating approaches in certain patient populations.

24 Sep 2026

Cannabis-derived nanovesicles showed early antitumor potential in mice

Researchers developed a Cannabis sativa hairy root culture system that produced stable plant-derived nanovesicles capable of promoting dendritic cell maturation and activating T-cell responses through TLR2- and TLR4-associated signaling. Oral administration also restored selected immune responses in immunosuppressed mice and suppressed tumor growth in an E.G7 lymphoma model, providing preliminary evidence for their immunomodulatory and antitumor potential.

15 Sep 2026

Chronic interferon exposure drives immunosuppression in tumors

Cancer biology and, in turn, cancer treatment have come a long way in the last few decades. Most people recognize this progress in breakthroughs like immunotherapy-a treatment strategy first deployed in 2011 that leverages the body's own immune cells to fight cancer and revolutionized the treatment landscape.

10 Sep 2026

Study links methylglyoxal stress to immunotherapy resistance in triple-negative cancer

The metabolism of cancer cells may play a key role in their ability to evade the immune system. This is demonstrated by a new study conducted by researchers at the University of Liège, which reveals how methylglyoxal stress – a by-product of tumor metabolism – promotes immunosuppression and the formation of metastases, and may contribute to resistance to immunotherapy and the progression of triple-negative cancer.

9 Sep 2026

Pig kidney xenotransplantation offers a bridge for patients awaiting human donor kidneys

In January 2026, Tim Andrews, who had received a genetically edited pig kidney in January 2025, became the recipient of a human kidney.

3 Sep 2026

Giving immunotherapy before surgery boosts brain tumor treatment success

A team from UNIGE and HUG has shown that administering cell immunotherapy before surgery to remove a brain tumor is significantly more effective than administering it afterwards.

2 Sep 2026

Newly identified cells protect lung tumors from immune attacks

Researchers at Columbia University have discovered a new type of cell that protects lung cancers from attacks by the immune system.

27 Aug 2026

Combined bio-histological score prevents overtreatment in liver transplant patients

Long‑term outcomes after liver transplantation remain hampered by complications linked to intensive immunosuppression—infections, cardiovascular events, kidney dysfunction, and metabolic disorders affect 10% to 40% of recipients.

24 Aug 2026

Glioma microenvironment emerges as key target for future therapies

The prognosis for glioma patients remains extremely poor despite aggressive multimodal standard therapy: maximal safe resection, radiotherapy, and temozolomide chemotherapy, with median survival rarely exceeding 15 to 18 months.

20 Aug 2026

Outfitting cells in "invisibility cloaks" could offer a novel approach to treating diabetes

Outfitting cells in "invisibility cloaks" may offer an easier, less damaging treatment pathway for people with diabetes undergoing cell therapy, according to researchers at Penn State.

14 Aug 2026

Study uncovers hidden switch that helps cancer cells to evade immune detection

Researchers from the Cancer Science Institute of Singapore (CSI Singapore) at the National University of Singapore (NUS) have uncovered a previously unknown mechanism that helps cancer cells evade detection by the body's immune system.

13 Aug 2026

Severe COVID-19 reactivates dormant viruses and may leave a lasting viral signature

A longitudinal study of 1,154 hospitalized COVID-19 patients found widespread reactivation of chronic Herpesviridae and Anelloviridae, with distinct viral patterns linked to disease severity, inflammation, and clinical outcomes. Anelloviridae also persisted during convalescence and were associated with physical deficits in long COVID, although the study did not establish causation.

7 Aug 2026

Localized biochemical halo of IL-10 suppresses immune rejection of pancreatic beta cells

A protein known as interleukin 10 (IL-10) is the lynchpin of a new method to protect transplanted cells from host immune system aggression.

6 Aug 2026

Discovery may help develop new treatments for immunosuppressed skin cancer patients

Researchers at The University of Texas MD Anderson Cancer Center have discovered that immunosuppressed patients with non-melanoma skin cancer are not missing the key cancer-fighting immune cells found in immunocompetent patients, but those cells – known as macrophages – have lost the ability to communicate effectively.

5 Aug 2026

Targeted dendritic cell vaccines emerge as a major step forward in cancer immunotherapy

A major step forward in cancer immunotherapy is emerging through the growing development of dendritic cell vaccines, a highly targeted approach designed to harness the body's own immune system to fight tumors.